0.19% -0.010

Pluri Inc (PLUR)

Pluri Inc Aktie (PLUR) Neueste Nachrichten

Pluri Inc (PLUR)

Pluri Inc Aktie (PLUR) Neueste Nachrichten

(PLUR) Proactive Strategies - Stock Traders Daily

Plurilock’s Behavioral Biometrics: Next-Gen Cybersecurity with Scott Meyers - The Deep Dive

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance

Plurilock Security joins forces with cloud platform for data protection - Mugglehead

Ever After Foods receives $10 million investment - Food Business News

Former CrowdStrike Director Reveals Plurilock’s Potential - The Deep Dive

(PLUR) Technical Pivots with Risk Controls - Stock Traders Daily

Pluri Unveils Proprietary 3D Cell Expansion Technology - Contract Pharma

Cyber Warfare: Ex-CIA Officer Warns of New Global Conflict, With Bryan Cunningham of Plurilock Security - The Deep Dive

Pluri (NASDAQ:PLUR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Critical Review - American Banking and Market News

(PLUR) Trading Advice - Stock Traders Daily

Critical Survey: Tevogen Bio (NASDAQ:TVGN) versus Pluri (NASDAQ:PLUR) - Defense World

Spanish seafood processors slam plant-based seafood labeling practices; Steakholder Foods signs MoU with Sherry Herring - SeafoodSource

Spanish seafood processors slam plant-based seafood labeling practices; Tender Food products now in Clover locations - SeafoodSource

Pluri Inc. faces potential Nasdaq delisting over equity shortfall - Investing.com

Pluri Inc. faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada

400% Stock Surge: What’s Next for Plurilock Security? | Ali Hakimzadeh - The Deep Dive

Pluri enters deal to manufacture Kadimastem’s AstroRx for ALS - ALS News Today

Pluri signs tech transfer, manufacturing agreement with Kadimastem - TipRanks

Pluri’s CDMO To Manufacture Kadimastem’s Cell Therapy Candidates - Contract Pharma

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates - Morningstar

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates - StockTitan

(PLUR) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Joe Sexton: Enhancing Plurilock’s Vision with Decades of Experience - The Deep Dive

Contrasting Pluri (NASDAQ:PLUR) & Relay Therapeutics (NASDAQ:RLAY) - American Banking and Market News

Plurilock Appoints Palantir Senior Advisor To Company’s Industry Advisory Council - The Deep Dive

Critical Comparison: Pluri (NASDAQ:PLUR) & Relay Therapeutics (NASDAQ:RLAY) - Defense World

Pluri (NASDAQ:PLUR) Trading 0.3% Higher - Defense World

Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs - Business Wire

Pluri Inc partners to boost global vegetable supply - Investing.com India

Pluri Inc partners to boost global vegetable supply By Investing.com - Investing.com Canada

Morgan Stanley raises TSMC shares target on strong demand outlook By Investing.com - Investing.com India

Seagate stock target raised, maintains Neutral stance on financial performance By Investing.com - Investing.com India

Strategic Agreement Sparks Market Interest In Pluri (PLUR) Stock - State Reviewer

Pluri Inc partners to boost global vegetable supply - Investing.com

Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply - StockTitan

Pluri announces proof of concept agreement with an agriculture corporation - TipRanks

BioCentriq Enhances Partnership With Pluristyx - Contract Pharma

Pluri Inc. appoints new CFO as current officer resigns By Investing.com - Investing.com South Africa

Pluri Inc. appoints new CFO as current officer resigns By Investing.com - Investing.com

Freshworks director Zachary Nelson sells $238,855 in company stock By Investing.com - Investing.com UK

Pluri Inc. Announces CFO Transition and New Appointment - TipRanks

Pluri Inc. appoints new CFO as current officer resigns - Investing.com

(PLUR) Investment Report - Stock Traders Daily

UBS Offshore Accounts: Sebi's Half Baked Case Against Indian Billionaires - BW Businessworld

Regulus reports positive ADPKD trial results at 3 mg/kg dose By Investing.com - Investing.com

Pluri subsidiary Ever After Foods secures $10M strategic investment - MSN

Pluri Inc partners to boost global vegetable supply By Investing.com - Investing.com

Dr. Michal Sheleg on a Novel Immunotherapy Platform for Solid Tumor Treatment - DocWire News

Pluri: Several Opportunities Across Different Sectors - Seeking Alpha

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food - EIN News

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges - StockTitan

Trend Tracker for (PLUR) - Stock Traders Daily

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight - The Malaysian Reserve

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight - Yahoo Finance

NIAID funds second year of Pluri's radiation therapy studies By Investing.com - Investing.com India

NIAID funds second year of Pluri's radiation therapy studies - Investing.com India

NIAID funds second year of Pluri's radiation therapy studies By Investing.com - Investing.com

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract - GlobeNewswire Inc.

3D Cell-Expansion Technology Revolutionizing Industries: Interview with Lior Raviv, Chief Technology Officer at Pluri - TechBullion

Ähnlich wie PLUR